trending Market Intelligence /marketintelligence/en/news-insights/trending/UOY991tkKFLkkdP6t93hmA2 content esgSubNav
In This List

Eyenovia files for $35M IPO

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Eyenovia files for $35M IPO

Eyenovia Inc. filed for an IPO of up to $35 million of its common stock.

The company has applied to list its common stock on the Nasdaq Capital Market under the symbol EYEN.

Net proceeds will be used to complete phase 3 clinical trials of company's products MicroProst and MicroStat, registration activities for MicroTears, and to complete scale-up engineering and manufacturing for pivotal trials and approval from the U.S. Food and Drug Administration. The proceeds will also be used for the completion of formulation work for each development program and for general corporate purposes, including working capital.

Eyenovia is a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-doses of active pharmaceutical ingredients, or micro-therapeutics, topically to the eye.

Ladenburg Thalmann & Co. Inc. and Roth Capital Partners LLC will act as underwriters for the offering.